NCT06881537

CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: Shanghai Changzheng Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This prospective, single-arm study aims to investigate the efficacy and safety of CapeOX combined with Bevacizumab plus Anti-PD1 Antibody as neoadjuvant therapy for locally recurrent colorectal cancer

Conditions

• Locally Recurrent Colorectal Cancer

Interventions

Type	Name	Description
DRUG	Capecitabine	Capecitabine is given orally at 1000mg / m² twice a day from day1-14 every 3 weeks for 4 cycles
DRUG	Oxaliplatin	Oxaliplatin is given by intravenous infusion at 130mg / m² on Day 1 every 3 weeks for 4 cycles
DRUG	Bevacizumab	Bevacizumab is given intravenously at 7.5mg/kg on day 1 every 3 weeks for 4 cycles
DRUG	Tislelizumab	Tislelizumab is given intravenously at 200 mg on day 1 every 3 weeks for 4 cycles

Timeline

• Start date: 2024-06-01
• Primary completion: 2025-06-30
• Completion: 2028-06-30
• First posted: 2025-03-18
• Last updated: 2025-03-18

Locations

1 site across 1 country: China